Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male and female patients aged ≥40 with stable moderate to severe COPD (GOLD guidelines).~* Post-salbutamol (FEV1) \< 80% and ≥ 30% of predicted normal value and Post-salbutamol FEV1/FVC \< 70%.~* Current or ex-smokers of 10 ≥pack-years.~Exclusion Criteria:~* Patients with no history or current diagnosis of asthma.~* No evidence of an exacerbation within 6 weeks prior to the screening visit.~* No evidence of clinically significant respiratory and/or cardiovascular conditions or laboratory abnormalities.~* No contraindication to use of anticholinergic drugs such as known symptomatic prostatic hypertrophy, bladder neck obstruction or narrow-angle glaucoma.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aclidinium bromide (Type: EXPERIMENTAL): Aclidinium bromide 400 µg administered twice per day during 6 weeks of treatment
- Tiotropium (Type: ACTIVE_COMPARATOR): Tiotropium bromide 18 µg administered once per day during 6 weeks of treatment
- Placebo (Type: PLACEBO_COMPARATOR): Placebo comparator administered during 6 weeks of treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).